Vidasym is a clinical-stage drug discovery/development company that invents and develops novel drugs for the indications of chronic kidney disease complications and osteoporosis.


VS-505: A novel phosphate binder derived from gum Arabic (GA) has been evaluated in a proof-of-concept clinical trial in hemodialysis patients; VS-505 is highly efficacious with minimal side effects suitable for treating phosphate imbalance in chronic kidney disease.

VS-105: A novel vitamin D receptor agonist is in Phase I clinical study for the treatment of osteoporosis and hyperparathyroidism secondary to chronic kidney disease. In the completed SAD/MAD studies, VS-105 exhibits a wide therapeutic index with no hypercalcemia, no AEs or other issues observed.